<DOC>
	<DOCNO>NCT00933231</DOCNO>
	<brief_summary>This multicentre study examine use Advagraf-minimization strategy and/or use inhibitor renin-angiotensin system reduce chronic rejection renal allograft .</brief_summary>
	<brief_title>Comparison Standard Versus Low Dose AdvagrafÂ® With Without Angiotensin-converting Enzyme Inhibitor ( ACEi ) /Angiotensin Receptor Blocker ( ARB ) Histology Function Renal Allografts</brief_title>
	<detailed_description>The study consist follow 4 treatment group . : 1 . Standard dose Advagraf angiotensin-converting enzyme inhibitor ( ACEi ) /angiotensin receptor blocker ( ARB ) antihypertensive therapy 2 . Standard dose Advagraf without ACEi/ARB antihypertensive therapy 3 . Low dose Advagraf ACEi/ARB antihypertensive therapy 4 . Low dose Advagraf without ACEi/ARB antihypertensive therapy</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>Subject recipient first second decease living donor renal transplant ( one kidney ) Subject must least one HLAmismatch donor . HLA identical donorrecipient pair eligible Subject understand either English French If female childbearing potential , subject negative pregnancy test utilizes adequate contraceptive method Presence donor specific antibody Subject currently participate study investigational drug , receive investigational drug within three month prior randomization . Observational study acceptable Subject lose previous graft immunological reason less one year transplant Subject pregnant breastfeeding Subject receive kidney lack preimplantation biopsy Subject significant disease ( e.g . malignancy uncontrolled infection ) disability ( e.g . cognitive defect ) prevent understanding , adherence protocol Subject opinion Investigator , require ACEi/ARB therapy posttransplant indication Subject require induction Thymoglobulin , Campath , antithymocyte globulin ( ATG ) , antilymphocyte globulin ( ALG ) biological induction agent basiliximab . Unplanned posttransplant use prohibit drug clinical indication posttransplant allow Subject plan become pregnant within 2 year posttransplant Subject positive Tcell Bcell crossmatch . Subjects weakly positive Bcell crossmatch test negative follow DTT reduction acceptable Subject requirement maintenance immunosuppressant therapy exception low dose steroid mycophenolate mofetil ( MMF ) . A subject low dose tacrolimus maintenance therapy eligible provide tacrolimus withhold least 1 week prior transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Advagraf</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Angiotensin-Converting Enzyme Inhibitors</keyword>
</DOC>